Aurélie Fugon
Senior Director, Commercial Strategy and Operations
Jonas Béal
Director of Solution Strategy
Presentation
Harnessing Spatial Biology and Agentic AI to Optimize ADC Clinical Development Strategies
- Antibody-drug conjugates (ADCs) represent a groundbreaking advancement in oncology, but they still face challenges.
- Through our operating system, Owkin K, we leverage Agentic AI and the world’s largest spatial and multi-omics dataset in oncology (MOSAIC) to decipher intra-patient tumor and tumor microenvironment heterogeneity.
- We analyze key ADC response factors, including target specificity, internalization, and payload sensitivity.
- By translating these biological hypotheses into quantifiable metrics and potential biomarkers, we guide indication selection, patient stratification, and combination therapy strategies for ADCs
- We showcase this approach by using a known ADC target as a case study (i.e., NECTIN4).
Date
April 29, 2025
Time
10:00 am
Abstract
Poster number
Spotlight Theater D